State of New Jersey Common Pension Fund D Purchases 29,810 Shares of Indivior PLC $INDV

State of New Jersey Common Pension Fund D increased its position in shares of Indivior PLC (NASDAQ:INDV) by 127.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 53,282 shares of the company’s stock after purchasing an additional 29,810 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Indivior were worth $1,912,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. CWM LLC bought a new position in Indivior in the 3rd quarter worth $25,000. Quarry LP bought a new position in Indivior in the 3rd quarter worth approximately $26,000. Raymond James Financial Inc. bought a new stake in shares of Indivior during the second quarter valued at approximately $26,000. Salomon & Ludwin LLC bought a new position in shares of Indivior during the fourth quarter worth $30,000. Finally, Harbor Capital Advisors Inc. grew its stake in Indivior by 309.9% during the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after acquiring an additional 781 shares in the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on INDV. Weiss Ratings cut shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday. Northland Securities set a $50.00 target price on shares of Indivior in a report on Tuesday, January 20th. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. Finally, HC Wainwright increased their price target on shares of Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Indivior has an average rating of “Buy” and a consensus target price of $39.33.

Indivior Stock Performance

INDV stock opened at $39.50 on Monday. The stock has a market cap of $4.82 billion, a PE ratio of 20.26 and a beta of 0.90. Indivior PLC has a 12 month low of $10.63 and a 12 month high of $41.00. The company has a 50-day moving average price of $32.24 and a 200 day moving average price of $32.85.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The business had revenue of $317.00 million during the quarter. Sell-side analysts forecast that Indivior PLC will post 3.35 EPS for the current year.

Insider Activity

In other Indivior news, Director Stuart A. Kingsley acquired 940 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was bought at an average price of $31.86 per share, for a total transaction of $29,948.40. Following the acquisition, the director directly owned 5,582 shares in the company, valued at $177,842.52. The trade was a 20.25% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.74% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.